Robert Deans

Dr. Deans is a serial entrepreneur who has deep expertise in the cell and gene therapy space. He is currently CSO at Synthego, a leading CRISPR company focused on developing and deploying full stack genome engineering solutions. Prior to Synthego, Deans served as CTO of Bluerock Therapeutics, where he was responsible for implementing a novel induced pluripotent stem cell production platform. He has more than 25 years of experience in stem cell therapeutics, including hematopoietic and mesenchymal stem cell (MSC) cells, gene therapy approaches, translational science, and global regulatory expertise. Deans previously served as CSO of Rubius Therapeutics, where he was responsible for the development of a gene-engineered red cell therapeutics platform. He holds a B.S. from the Massachusetts Institute of Technology and a Ph.D. in microbiology from the University of Michigan.